MSLN and cancer: Even though the actual clinical efficacy of such approaches is still to be demonstrated in PM, targeting this TAA remains of interest for cancer therapy, as illustrated by encouraging recent results with anti-MSLN chimeric antigen receptor-T-cells (CAR-T) and the ever-growing number of ongoing clinical trials targeting MSLN in various cancers.16